

**DCF Psychotropic Medication Advisory Committee**  
**May 3, 2013 1:00PM**  
**Albert J. Solnit Children's Center, Middletown, CT.**  
**Meeting Notes**

Present: Lesley Siegel, M.D. Chair; David Aresco, RPh; Chris Malinowski, APRN; Joan Narad, M.D.; Allen Alton, M.D.; Irvin Jennings, M.D.; Bryan Keyes, M.D.; Aurele Kamm, APRN; Margaret Rudin, APRN, PhD; Sherrie Sharp M.D.; Debra Brown, M.D.; Fredericka Wolman, M.D., MPH.

1. Call to order: Dr. Siegel called the meeting to order at 1:11pm.
2. Set date/time of next meeting: A suggestion was made to meet via conference call every other month and live every other month. The Committee did not endorse the suggestion. The next meeting is scheduled for June 7, 2013 from 1pm – 2:30pm; Solnit Center AB conference room. There will be no meetings scheduled for July and August 2013.
3. Minutes: Review and approve minutes of the April 2013 meeting. Correction: To minor changes: in 2 spots change April to May. Minutes approved with this change.
4. Announcements.
  - Dr. Siegel attended an excellent DDS sponsored training forum this AM (5/3/13). The training was completed by Dr. Pavin, M.D. (Neurology) and Dr. Charlot, PD, LISW (Psychiatry). The presentation will be posted on the DDS web site, and she encouraged committee members to review it.
    - The topic was medications, side effects and movement disorders.
    - Presentation titled: "When in Doubt Rule it Out" explored the possibility of side effects of medications masquerading as psychological symptoms.
5. Old Business:
  - Approved Drug List
    - Modify list format: include FDA approval criteria to include age and diagnosis: The second and revised version of a draft document was distributed and reviewed in detail. The content was reviewed/discussed in addition to the format. Several modifications were recommended (see below) and will be made and brought to the June 2013 meeting for final approval.
      - Put age detail back in child section
      - Place heading on each page
      - Change "Non psychiatric indication" to "None"
      - Add various brand names of clozapine

- Change order from A, D, AD to C, AD, A in last 3 columns.
- Remove all tall man lettering
- Remove the \* from all drug names and remove footer referring to Drug Use Guidelines.
- At the June meeting review the need to include doxepin, loxapine, and oxazepam given that they are rarely prescribed in the child/adolescent population.

6. New Business:

- Controlled drug tracking: Mr. Aresco described the Department of Consumer Protection (Controlled Drug Division) automated system for tracking potential control drug diversion in the outpatient setting. PMAC members request information regarding what they as prescribers have access to in this system (data-base). Mr. Aresco will inquire and report back at the June 2013 meeting.
- Medicaid/Foster Care Antipsychotic Measures: Public Comment:: The document was distributed, reviewed and discussed in detail. Note that Dr. Siegel in on the Foster Care Advisory Panel that is working with NCINQ (National Collaborative for Innovation in Quality Measurement, a division of HHS). There is a “comment” period to send in feedback on this document that lasts until May 17, 2013. PMAC members are encouraged to provide feedback.
  - Details of Proposed Measure # 4 (pg 8) were discussed. ("Use of antipsychotics in children without a primary indication"). Committee members wondered why PTSD wasn't noted as a primary indication for the use of antipsychotic medication, but also commented that another primary indication was in the treatment of aggression (see TRAY recommendations) but that aggression is a symptom, and is not diagnosis specific. In general the group thought this measure was too questionable to be included.
  - Each of 7 key points were reviewed and discussed.
  - FDA indications discussed. Clarification needed in the document.
  - Members noted that the decreased length of stay (inpatient) and decreased access to other resources (non pharmacological) may be part of the reason for an increase in the utilization of the SGAs (second generation antipsychotic medications).
- Dr. Siegel will relate these issues via conference call next week.

7. Adjournment: the meeting was adjourned at 2:30pm

Respectfully Submitted:  
David S. Aresco, RPh, FASCP